Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation. 1979;59:585-588

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Armstrong, P. W.
Right arrow Articles by Marks, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armstrong, P. W.
Right arrow Articles by Marks, G. S.

Circulation, Vol 59, 585-588, Copyright © 1979 by American Heart Association

ARTICLES

Blood levels after sublingual nitroglycerin

PW Armstrong, JA Armstrong and GS Marks

Pharmacokinetic analysis of nitroglycerin (GTN) has been hampered by the lack of a sensitive and specific method for measuring GTN in blood. Therefore, we examined the appearance of GTN in blood after administering 0.6 mg sublingually in 10 studies of normal volunteers. We used a gas-liquid chromatographic method with electron-capture detection and isosorbide dinitrate as the internal standard. GTN appeared in blood at 0.5 minutes, reached a peak of 2.3 +/- 0.36 ng/ml at 2 minutes, fell to 50% of peak value at 7.5 minutes and was barely detectable at 20 minutes. These blood levels paralleled the changes in heart rate and systolic blood pressure. These data show rapid appearance and disappearance of GTN from blood after sublingual administration, a large volume of distribution, and a rapid rate of total body clearance that precludes the liver from being the sole elimination site. This method for analysis of GTN and isosorbide dinitrate should be helpful in defining the role of chronic nitrate therapy.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
J. M. DiFabio, G. R. Thomas, L. Zucco, M. A. Kuliszewski, B. M. Bennett, M. J. Kutryk, and J. D. Parker
Nitroglycerin Attenuates Human Endothelial Progenitor Cell Differentiation, Function, and Survival
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 117 - 123.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
D. A. Zvara
Treatment of Perioperative Myocardial Ischemia
Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 2001; 5(2): 166 - 183.
[Abstract] [PDF]

Home page
 J Biomater ApplHome page
M. Szycher
Recent Advances in Transdermal Delivery Systems
J Biomater Appl, January 1, 1986; 1(2): 207 - 238.
[PDF]

Home page
 ANGIOLOGYHome page
A. Karim
Transdermal Absorption of Nitroglycerin from Microseal Drug Delivery (MDD) System
Angiology, January 1, 1983; 34(1): 11 - 22.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
R. H. Thompson
The Clinical Use of Transdermal Delivery Devices with Nitroglycerin
Angiology, January 1, 1983; 34(1): 23 - 31.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
W. A. Pitt, R. G. Friedman, S. A. Gross, J. Glassman, E. C. Keating, and J. H. Mazur
Effect of Intravenous Nitroglycerin on Hemodynamics of Congestive Heart Failure
Angiology, May 1, 1982; 33(5): 294 - 301.
[Abstract] [PDF]


Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1979 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.